

Supplementary Table 1. Treatment results with Anti-VEGF injection from randomized clinical and real-life data studies

STUDIES	PATIENT NUMBER (n)	Anti-VEGF (Ranibizumab 0.5 mg Afibercept 2 mg)	TREATMENT REGIMEN	1. YEAR			2. YEAR			3. YEAR						
				LETTER GAIN	CMT DECREASE	INJECTION NUMBER	VISIT NUMBER	LETTER GAIN	CMT DECREASE	INJECTION NUMBER	VISIT NUMBER	LETTER GAIN	CMT DECREASE	INJECTION NUMBER	VISIT NUMBER	
ANCHOR(13)	423	Ranibizumab	Monthly	11,3	N/A	12	12	10,7	N/A	12	12	N/A	N/A	N/A	N/A	
MARINA(7)	716	Ranibizumab	Monthly	7,2	N/A	12	12	6,6	N/A	12	12	N/A	N/A	N/A	N/A	
VIEW 1(9)	1217	Afibercept	first year 1 in 2 months -PRN	7,9	128,5	8	8	7,6	139	4,2	12	N/A	N/A	N/A	N/A	
VIEW 2(9)	1240	Afibercept	first year 1 in 2 months -PRN	8,9	149,2	8	8					N/A	N/A	N/A	N/A	
AURA(14)	1695	Ranibizumab	PRN	2,4	N/A	5	8,6	0,6	N/A	2,2	4,9	N/A	N/A	N/A	N/A	
Kim et al(10)	26.360	Ranibizumab	PRN	3,5	N/A	5,4	8,6	1,5	N/A	3,7	9,2	-1,9	N/A	2,8	8,2	
Horner et al(17)	86	Ranibizumab	PRN	6,9	N/A	6	N/A	4,1	N/A	4	N/A	-0,8	N/A	4	N/A	
RAINBOW(15)	516	Afibercept	PRN	5,3	111	6,3	9,8	2,3	108	3,5	7,05	0,4	119	3,2	6,7	
PERSEUS(18)	803	Afibercept	PRN	3,5	N/A	5,9	9,2	1,8	N/A	2,1	4,6	N/A	N/A	N/A	N/A	
Almuhaseb et al (19)	1083	Afibercept	first year 1 in 2 months -PRN	5	N/A	7-8	8	2,8	N/A	3,7	12	N/A	N/A	N/A	N/A	
Chandra et al(20)	468	Afibercept	T&E	5,6	N/A	7,8	N/A	3	N/A	4,9	N/A	0,3	N/A	3,8	N/A	
Cebeci et al(11)	89	Ranibizumab	PRN	8,9	89	5,8	8,4	8,3	94	4,2	6,6	N/A	N/A	N/A	N/A	
Sizmaz et al(12)	73	Ranibizumab	PRN	3,6	59,6	6,5	12	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
	68	Afibercept	PRN	3,2	121,1	6,4	12	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
LUMINOUS(16)	30.148	Ranibizumab	PRN/T&E	-1,6	N/A	4,7	8,1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
Australia	978			-1,2	N/A	7,5	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Canada	1158			-0,7	N/A	7,5	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chinese	99			-2,2	N/A	2,2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
France	277			-2,1	N/A	4	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Germany	158			-1,3	N/A	4,6	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hungary	245			-3,8	N/A	2,9	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Japan	783			-0,7	N/A	3,4	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Poland	208			-0,1	N/A	3,1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Portugal	173			-4,9	N/A	1,9	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UK	4683			-2	N/A	4,5	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Our study	140			Ranibizumab	PRN	4,8	73	3,7	7,6	0,4	103	1	6	-2,2	86	1
	105	Afibercept	PRN	1,5	88	4	7,9	-2,9	87	1,6	5,7	-6,4	86	1	2,3	

CMT: central macular thickness; PRN: pro re nata; T&E: treat and extend; N/A: not available; INJ: injection